Peptide-Targeted Elastin Nanoparticles Deliver Paclitaxel Directly to Ovarian Cancer Cells | Research

The takeaway

AP1 peptide-functionalized elastin-like polypeptide nanoparticles selectively delivered paclitaxel to ovarian cancer cells through IL-4R targeting, improving drug accumulation and reducing off-target effects.

Peptide GPS for chemo
AP1 peptide guides elastin nanoparticles specifically to ovarian cancer cells through IL-4 receptor targeting

What the researchers found

AP1-functionalized ELP nanoparticles selectively delivered paclitaxel to ovarian cancer via IL-4R targeting with improved tumor accumulation and reduced off-target toxicity.

Why it matters

Ovarian cancer is often diagnosed late with limited treatment options. Peptide-targeted delivery could make existing chemotherapy drugs more effective and less toxic.

How the study worked

Design and characterization of AP1-ELP nanoparticles loaded with paclitaxel, cellular uptake studies, IL-4R targeting validation, and in vivo ovarian cancer model evaluation.

What this study cannot tell us

Preclinical study. IL-4R expression varies across ovarian cancer subtypes. Manufacturing scale-up of recombinant ELPs not fully addressed.

How to read the evidence

Preclinical proof-of-concept with in vivo validation. Promising targeted delivery approach.

When this study was published

Published in 2025.

The bigger picture

Elastin-like polypeptides are uniquely versatile: they self-assemble into nanoparticles, can be genetically fused with targeting peptides, and are fully biocompatible—an elegant drug delivery platform.

Questions still open

Which ovarian cancer subtypes express sufficient IL-4R for AP1 targeting?
Could this ELP platform deliver other chemotherapy drugs?
How does AP1-ELP compare to antibody-drug conjugates for ovarian cancer?

Common questions

How does peptide targeting improve chemotherapy?

The AP1 peptide acts like a GPS system, guiding paclitaxel-loaded nanoparticles directly to cancer cells that display IL-4 receptors. This concentrates the drug at the tumor while reducing damage to healthy tissue.

What are elastin-like polypeptides?

They are protein-based materials inspired by natural elastin. They can be genetically programmed to self-assemble into nanoparticles and carry drugs, all while being fully biocompatible with the body.

Read the original research

Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.

BMC cancer, 26(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Goel, Ridhima; Alvi, Shakeel; Ali, Rashid; Sharma, Pradeep; Bhattacharyya, Jayanta; Sarangthem, Vijaya; Singh, Thoudam Debraj. (2026). Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.. BMC cancer, 26(1). https://doi.org/10.1186/s12885-026-15615-0